168 related articles for article (PubMed ID: 38595234)
21. Identification of hub genes and regulatory factors of glioblastoma multiforme subgroups by RNA-seq data analysis.
Li Y; Min W; Li M; Han G; Dai D; Zhang L; Chen X; Wang X; Zhang Y; Yue Z; Liu J
Int J Mol Med; 2016 Oct; 38(4):1170-8. PubMed ID: 27572852
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel prognostic targets in glioblastoma using bioinformatics analysis.
Yin X; Wu Q; Hao Z; Chen L
Biomed Eng Online; 2022 Apr; 21(1):26. PubMed ID: 35436915
[TBL] [Abstract][Full Text] [Related]
23. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
Vachher M; Arora K; Burman A; Kumar B
J Cell Biochem; 2020 Apr; 121(4):3010-3023. PubMed ID: 31710121
[TBL] [Abstract][Full Text] [Related]
24. "Zooming in" on Glioblastoma: Understanding Tumor Heterogeneity and its Clinical Implications in the Era of Single-Cell Ribonucleic Acid Sequencing.
Khalafallah AM; Huq S; Jimenez AE; Serra R; Bettegowda C; Mukherjee D
Neurosurgery; 2021 Feb; 88(3):477-486. PubMed ID: 32674143
[TBL] [Abstract][Full Text] [Related]
25. A Promising Glycolysis- and Immune-Related Prognostic Signature for Glioblastoma.
Wang F; Liu X; Jiang H; Chen B
World Neurosurg; 2022 May; 161():e363-e375. PubMed ID: 35144031
[TBL] [Abstract][Full Text] [Related]
26. A comprehensive prognostic signature for glioblastoma patients based on transcriptomics and single cell sequencing.
Fan F; Zhang H; Dai Z; Zhang Y; Xia Z; Cao H; Yang K; Hu S; Guo Y; Ding F; Cheng Q; Zhang N
Cell Oncol (Dordr); 2021 Aug; 44(4):917-935. PubMed ID: 34142341
[TBL] [Abstract][Full Text] [Related]
27. EMP3 as a prognostic biomarker correlates with EMT in GBM.
Li L; Xia S; Zhao Z; Deng L; Wang H; Yang D; Hu Y; Ji J; Huang D; Xin T
BMC Cancer; 2024 Jan; 24(1):89. PubMed ID: 38229014
[TBL] [Abstract][Full Text] [Related]
28. Novel LncRNA OXCT1-AS1 indicates poor prognosis and contributes to tumorigenesis by regulating miR-195/CDC25A axis in glioblastoma.
Zhong C; Yu Q; Peng Y; Zhou S; Liu Z; Deng Y; Guo L; Zhao S; Chen G
J Exp Clin Cancer Res; 2021 Apr; 40(1):123. PubMed ID: 33832517
[TBL] [Abstract][Full Text] [Related]
29. Quiescent stem cell marker genes in glioma gene networks are sufficient to distinguish between normal and glioblastoma (GBM) samples.
Mukherjee S
Sci Rep; 2020 Jul; 10(1):10937. PubMed ID: 32616845
[TBL] [Abstract][Full Text] [Related]
30. Differential expression of the circadian clock network correlates with tumour progression in gliomas.
Petkovic M; Yalçin M; Heese O; Relógio A
BMC Med Genomics; 2023 Jul; 16(1):154. PubMed ID: 37400829
[TBL] [Abstract][Full Text] [Related]
31. DKK3 expression is associated with immunosuppression and poor prognosis in glioblastoma, in contrast to lower-grade gliomas.
Han MH; Baek JM; Min KW; Cheong JH; Ryu JI; Won YD; Kwon MJ; Koh SH
BMC Neurol; 2023 May; 23(1):183. PubMed ID: 37149563
[TBL] [Abstract][Full Text] [Related]
32. Integrated microenvironment-associated genomic profiles identify LRRC15 mediating recurrent glioblastoma-associated macrophages infiltration.
Tang H; Liu W; Xu Z; Zhao J; Wang W; Yu Z; Wei M
J Cell Mol Med; 2021 Jun; 25(12):5534-5546. PubMed ID: 33960636
[TBL] [Abstract][Full Text] [Related]
33. Establishment and validation of an immune-based prognostic score model in glioblastoma.
Qin Z; Zhang X; Chen Z; Liu N
Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
[TBL] [Abstract][Full Text] [Related]
34. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract][Full Text] [Related]
35. Integrative multi-omics characterization reveals sex differences in glioblastoma.
Jang B; Yoon D; Lee JY; Kim J; Hong J; Koo H; Sa JK
Biol Sex Differ; 2024 Mar; 15(1):23. PubMed ID: 38491408
[TBL] [Abstract][Full Text] [Related]
36. Exploring the Correlation of Abnormal CXCL9 Expression with Immune Infiltration in Glioma and Patient Prognosis Based on TCGA and GTEx Databases.
Liao Y; Liu B; Jin C; Liao X; Zhang Z
J Mol Neurosci; 2022 Dec; 72(12):2413-2424. PubMed ID: 36449138
[TBL] [Abstract][Full Text] [Related]
37. Integrative analysis of KIF4A, 9, 18A, and 23 and their clinical significance in low-grade glioma and glioblastoma.
Cho SY; Kim S; Kim G; Singh P; Kim DW
Sci Rep; 2019 Mar; 9(1):4599. PubMed ID: 30872592
[TBL] [Abstract][Full Text] [Related]
38. Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for Glioblastoma.
Yu W; Ma Y; Hou W; Wang F; Cheng W; Qiu F; Wu P; Zhang G
Front Immunol; 2021; 12():706936. PubMed ID: 34899682
[TBL] [Abstract][Full Text] [Related]
39. Single-cell atlas reveals the immunosuppressive microenvironment and Treg cells landscapes in recurrent Glioblastoma.
Wang X; Ge Y; Hou Y; Wang X; Yan Z; Li Y; Dong L; She L; Tang C; Wei M; Zhang H
Cancer Gene Ther; 2024 May; 31(5):790-801. PubMed ID: 38429367
[TBL] [Abstract][Full Text] [Related]
40. Identification of Hypoxia Prognostic Signature in Glioblastoma Multiforme Based on Bulk and Single-Cell RNA-Seq.
Ahmed YB; Ababneh OE; Al-Khalili AA; Serhan A; Hatamleh Z; Ghammaz O; Alkhaldi M; Alomari S
Cancers (Basel); 2024 Feb; 16(3):. PubMed ID: 38339384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
